Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL CHRISTOPHER JOYCE

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1700045713
CMS profile
77679
Location
SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,632.70

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $2,425.95 6
ABBVIE INC. $171.31 2
Lilly USA, LLC $35.44 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL CHRISTOPHER JOYCE

NPI 1700045713 · CMS profile ID 77679

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700045713?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700045713?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700045713?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700045713?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $2,632.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $1,812.0010/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938742589 CMS
GENZYME CORPORATION $453.0010/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938742591 CMS
GENZYME CORPORATION $115.6910/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938742593 CMS
GENZYME CORPORATION $5.1910/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938742573 CMS
GENZYME CORPORATION $29.5909/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938742563 CMS
Lilly USA, LLC $35.4408/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918089365 CMS
ABBVIE INC. $119.0305/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892976031 CMS
ABBVIE INC. $52.2804/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892976027 CMS
GENZYME CORPORATION $10.4803/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938742511 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $700.40 2
PY2020 $2,376.00 1
PY2021 $2,246.65 3
PY2022 $2,632.70 9
PY2023 $23,671.61 40
PY2024 $79,055.13 79
PY2025 $92,566.63 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,750.00 4
PY2025 Principal investigator $694,810.55 184
PY2024 Recipient $7,148.03 20
PY2024 Principal investigator $657,792.45 167
PY2023 Recipient $3,281.97 14
PY2023 Principal investigator $421,779.06 92
PY2022 Recipient $1,517.38 3
PY2022 Principal investigator $234,287.76 66
PY2021 Principal investigator $111,180.61 56
PY2020 Principal investigator $343,493.78 70
PY2019 Principal investigator $4,975.53 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

188 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140249
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140253
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140257
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140261
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140265
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140269
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140271
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140275
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140280
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140284
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140288
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140292
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140656
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140660
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140663
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140667
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140671
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140675
Principal investigator 1 SANOFI US SERVICES INC. $2,603.70 12/22/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140647
Principal investigator 1 SANOFI US SERVICES INC. $3,344.00 12/08/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140637
Principal investigator 1 SANOFI US SERVICES INC. $3,021.00 12/08/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140643
Principal investigator 1 Incyte Corporation $3,844.80 12/04/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532230
Principal investigator 1 Incyte Corporation $5,149.50 12/04/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532234
Principal investigator 1 SANOFI US SERVICES INC. $4,349.40 11/17/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140631
Principal investigator 1 Incyte Corporation $5,724.00 11/14/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532225
Principal investigator 1 ABBVIE INC. $1,389.50 11/04/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417181
Recipient GENZYME CORPORATION $500.00 10/24/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226080341
Principal investigator 1 SANOFI US SERVICES INC. $8,849.00 10/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140560
Principal investigator 1 Incyte Corporation $1,879.20 10/16/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532218
Principal investigator 1 SANOFI US SERVICES INC. $3,181.20 10/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140556
Principal investigator 1 ABBVIE INC. $1,816.48 10/09/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417153
Principal investigator 1 Incyte Corporation $4,209.30 10/09/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532221
Principal investigator 1 Incyte Corporation $2,330.10 09/23/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532214
Principal investigator 1 SANOFI US SERVICES INC. $283.00 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140567
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140572
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140575
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140580
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140585
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140589
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140593
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140596
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140600
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140607
Principal investigator 1 SANOFI US SERVICES INC. $897.35 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140611
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140615
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140619
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140622
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140625
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140628
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226080333
Principal investigator 1 SANOFI US SERVICES INC. $2,125.20 09/15/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140548
Principal investigator 1 SANOFI US SERVICES INC. $10,482.00 09/15/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140552
Principal investigator 1 SANOFI US SERVICES INC. $1,470.00 09/04/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140603
Principal investigator 1 Incyte Corporation $250.00 09/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486801
Principal investigator 1 Incyte Corporation $5,400.00 09/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486808
Principal investigator 1 Incyte Corporation $7,192.10 08/26/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240486981
Principal investigator 1 SANOFI US SERVICES INC. $20,678.38 08/25/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140536
Principal investigator 1 Incyte Corporation $90.00 08/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486825
Principal investigator 1 Incyte Corporation $2,194.20 08/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240486986
Principal investigator 1 Incyte Corporation $2,208.60 08/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486830
Principal investigator 1 SANOFI US SERVICES INC. $2,372.70 08/11/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140532
Principal investigator 1 ABBVIE INC. $518.60 08/05/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417111
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/28/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175213817
Principal investigator 1 Janssen Research & Development, LLC $500.00 07/28/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175213949
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/28/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175214088
Principal investigator 1 Incyte Corporation $4,388.40 07/22/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532210
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 07/17/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175213697
Principal investigator 1 Incyte Corporation $2,027.70 07/16/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486812
Principal investigator 1 SANOFI US SERVICES INC. $2,785.20 07/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140437
Principal investigator 1 Incyte Corporation $6,481.80 07/10/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532201
Principal investigator 1 Incyte Corporation $990.00 07/10/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532205
Principal investigator 1 Incyte Corporation $242.00 07/07/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486818
Principal investigator 1 SANOFI US SERVICES INC. $132.00 07/02/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140441
Principal investigator 1 SANOFI US SERVICES INC. $8,962.00 07/02/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140524
Principal investigator 1 Incyte Corporation $2,027.70 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486728
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140425
Principal investigator 1 SANOFI US SERVICES INC. $897.35 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140427
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140430
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140433
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140443
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140447
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140451
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140457
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140459
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140462
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140467
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140470
Principal investigator 1 SANOFI US SERVICES INC. $897.35 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140473
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140476
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140480
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140484
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140488
Principal investigator 1 SANOFI US SERVICES INC. $283.00 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140492
Principal investigator 1 SANOFI US SERVICES INC. $897.35 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140496
Principal investigator 1 SANOFI US SERVICES INC. $897.35 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140500
Principal investigator 1 SANOFI US SERVICES INC. $897.35 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140504
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140508
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140512
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140516
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/20/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140520
Principal investigator 1 SANOFI US SERVICES INC. $8,738.40 06/16/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140421
Principal investigator 1 Incyte Corporation $90.00 06/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486702
Principal investigator 1 Incyte Corporation $90.00 06/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486708
Principal investigator 1 Incyte Corporation $90.00 06/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486733
Principal investigator 1 Incyte Corporation $569.00 06/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486746
Principal investigator 1 Incyte Corporation $264.00 06/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486758
Principal investigator 1 Incyte Corporation $484.00 06/13/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486789
Principal investigator 1 Incyte Corporation $6,481.80 06/12/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532190
Principal investigator 1 Incyte Corporation $99.00 06/12/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532194
Principal investigator 1 SANOFI US SERVICES INC. $5,768.00 06/09/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140417
Principal investigator 1 Incyte Corporation $132.00 06/06/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486752
Principal investigator 1 Incyte Corporation $119.00 06/06/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486782
Principal investigator 1 Incyte Corporation $165.00 06/06/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486795
Principal investigator 1 Incyte Corporation $6,481.80 06/05/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532197
Principal investigator 1 Amgen Inc. $4,575.00 06/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246637676
Principal investigator 1 Incyte Corporation $45.80 06/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486768
Recipient GENZYME CORPORATION $500.00 05/29/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226080329
Recipient GENZYME CORPORATION $250.00 05/29/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226080337
Principal investigator 1 Eli Lilly and Company $6,307.98 05/28/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187872363
Principal investigator 1 SANOFI US SERVICES INC. $17,650.00 05/27/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226140413
Principal investigator 1 Janssen Research & Development, LLC $3,813.64 05/15/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175214080
Principal investigator 1 Incyte Corporation $2,573.00 05/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486714
Principal investigator 1 Incyte Corporation $1,697.60 05/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486719
Principal investigator 1 Incyte Corporation $2,537.00 05/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486740
Principal investigator 1 SANOFI US SERVICES INC. $18,900.00 05/12/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226140409
Principal investigator 1 ABBVIE INC. $1,816.48 05/06/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417084
Principal investigator 1 Incyte Corporation $45.00 05/01/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532186
Principal investigator 1 Janssen Research & Development, LLC $3,813.64 04/28/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175213782
Principal investigator 1 Incyte Corporation $2,087.10 04/16/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486777
Principal investigator 1 SANOFI US SERVICES INC. $75,417.00 04/14/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140405
Principal investigator 1 Incyte Corporation $2,395.80 04/11/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486763
Principal investigator 1 Incyte Corporation $500.00 04/08/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532168
Principal investigator 1 ABBVIE INC. $2,043.68 04/03/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417077
Principal investigator 1 Incyte Corporation $3,500.00 04/01/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532164
Principal investigator 1 Incyte Corporation $2,000.00 04/01/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532173
Principal investigator 1 Incyte Corporation $10.00 04/01/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532177
Principal investigator 1 Incyte Corporation $13,200.00 04/01/2025 Non-covered Recipient Entity
ENDEAVOR HEALTHNORTHSHORE KELLOGG CANCER CENTER EVANSTON
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240532181
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140330
Principal investigator 1 SANOFI US SERVICES INC. $897.35 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140333
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140340
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140343
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140347
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140350
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140353
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140356
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140359
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140362
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140364
Principal investigator 1 SANOFI US SERVICES INC. $897.35 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140368
Principal investigator 1 SANOFI US SERVICES INC. $897.35 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140372
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140374
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140382
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140387
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140392
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140397
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226140401
Principal investigator 1 Incyte Corporation $2,253.00 03/19/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486622
Principal investigator 1 Incyte Corporation $2,319.00 03/19/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486629
Principal investigator 1 Incyte Corporation $1,751.40 03/19/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486634
Principal investigator 1 SANOFI US SERVICES INC. $18,054.25 03/10/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140296
Principal investigator 1 SANOFI US SERVICES INC. $2,082.00 03/10/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140299
Principal investigator 1 SANOFI US SERVICES INC. $3,636.00 03/04/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140303
Principal investigator 1 SANOFI US SERVICES INC. $17,400.00 03/04/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226140308
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486665
Principal investigator 1 Incyte Corporation $3,383.20 03/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486673
Principal investigator 1 Incyte Corporation $4,229.00 03/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486678
Principal investigator 1 Janssen Research & Development, LLC $11,395.55 03/03/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175213868
Principal investigator 1 SANOFI US SERVICES INC. $8,260.00 02/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140321
Principal investigator 1 SANOFI US SERVICES INC. $5,178.70 02/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226140326
Principal investigator 1 Incyte Corporation $3,751.00 02/21/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486603
Principal investigator 1 Incyte Corporation $2,573.00 02/21/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486610
Principal investigator 1 Incyte Corporation $1,395.30 02/21/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486614
Principal investigator 1 Incyte Corporation $472.61 02/12/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240486697
Principal investigator 1 Amgen Inc. $82,848.01 02/05/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246637672
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486646
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486653
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486659
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486684
Principal investigator 1 Janssen Research & Development, LLC $966.00 02/04/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175214045
Principal investigator 1 Incyte Corporation $1,945.20 01/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486583
Principal investigator 1 Incyte Corporation $2,253.00 01/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486589
Principal investigator 1 Incyte Corporation $2,253.00 01/24/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486597
Principal investigator 1 Incyte Corporation $2,694.33 01/23/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240486691
Principal investigator 1 Janssen Research & Development, LLC $3,768.27 01/16/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175213746
Principal investigator 1 Incyte Corporation $60.00 01/08/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240486640
Principal investigator 1 Amgen Inc. $15,189.41 01/06/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246637678
Principal investigator 1 ABBVIE INC. $2,175.98 01/02/2025 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202417037
Principal investigator 1 Amgen Inc. $119,750.63 01/02/2025 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246637670